Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice

Journal of Psychopharmacology

Volumn 26, Issue 5, 2012, Pages 724-732

  Sharma, Ajaykumar N ^a   Elased, Khalid M ^a   Lucot, James B ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

behavior; db db mice; depression; Diabetes; insulin resistance; insulin sensitizer; psychosis; PTSD; rosiglitazone

Indexed keywords

GLUCOSE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; FORCED SWIMMING TEST; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE UTILIZATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOCOMOTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPEN FIELD TEST; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BLOOD GLUCOSE; DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; EMOTIONS; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MOTOR ACTIVITY; PSYCHOTIC DISORDERS; SWIMMING; THIAZOLIDINEDIONES;

EID: 84861822831     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111434620     Document Type: Article

References (70)

1. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001 ; 24 (6). 1069-1078
2. Barber M, Kasturi BS, Austin ME, Patel KP, MohanKumar SM, MohanKumar PS. Diabetes-induced neuroendocrine changes in rats: role of brain monoamines, insulin and leptin. Brain Res. 2003 ; 964 (1). 128-135
3. Butler SG, Meegan MJ. Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter. Curr Med Chem. 2008 ; 15 (17). 1737-1761
4. Castaneda TR, Nogueiras R, Muller TD, et al. Decreased glucose tolerance and plasma adiponectin: resistin ratio in a mouse model of post-traumatic stress disorder. Diabetologia. 2011 ; 54 (4). 900-909
5. Chen CC, Yang JC. Effects of short and long-lasting diabetes mellitus on mouse brain monoamines. Brain Res. 1991 ; 552 (1). 175-179
6. Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996 ; 84 (3). 491-495
7. Cheta D, Dumitrescu C, Georgescu M, et al. A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabete Metab. 1990 ; 16 (1). 11-15
8. Chew W, Kucharczyk J, Moseley M, Derugin N, Norman D. Hyperglycemia augments ischemic brain injury: in vivo MR imaging/spectroscopic study with nicardipine in cats with occluded middle cerebral arteries. AJNR Am J Neuroradiol. 1991 ; 12 (4). 603-609
9. Chua SC, Chung WK, Wu-Peng XS, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996 ; 271 (5251). 994-996
10. Cincotta AH, Tozzo E, Scislowski PW. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci. 1997 ; 61 (10). 951-956
11. Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care. 2006 ; 29 (4). 786-791
12. Cohen N. Treatment of mental illness at home by small doses of insulin; a follow-up report and appraisal of results in 26 cases. N Engl J Med. 1949 ; 240 (17). 669-676
13. Coleman DL. Lessons from studies with genetic forms of diabetes in the mouse. Metabolism. 1983 ; 32 (7 Suppl 1). 162-164
14. Coleman DL, Hummel KP. Hyperinsulinemia in pre-weaning diabetes (db) mice. Diabetologia. 1974 ; 10: 607-610
15. Collins MM, Corcoran P, Perry IJ. Anxiety and depression symptoms in patients with diabetes. Diabet Med. 2009 ; 26 (2). 153-161
16. Contreras F, Foullioux C, Pacheco B, et al. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects. Am J Ther. 2008 ; 15 (4). 397-402
17. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 ; 148 (11). 1474-1486
18. Davis M. Pharmacological analysis of fear-potentiated startle. Braz J Med Biol Res. 1993 ; 26 (3). 235-260
19. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008 ; 2 (6). 1101-1113
20. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007 ; 64 (3). 327-337
21. Eissa Ahmed AA, Al-Rasheed NM, Al-Rasheed NM. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol. 2009 ; 20 (7). 635-642
22. Fetissov SO, Meguid MM, Sato T, Zhang LH. Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. Am J Physiol Regul Integr Comp Physiol. 2002 ; 283 (4). R905 - R910
23. Figlewicz DP, Brot MD, McCall AL, Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res. 1996 ; 736 (1-2). 54-60
24. Gainetdinov RR. Mesolimbic dopamine in obesity and diabetes. Am J Physiol Regul Integr Comp Physiol. 2007 ; 293 (2). R601 - R602
25. Garcia-Tornadu I, Ornstein AM, Chamson-Reig A, et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology. 2010 ; 151 (4). 1441-1450
26. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000 ; 23 (11). 542-549
27. Hall PA, Rodin GM, Vallis TM, Perkins BA. The consequences of anxious temperament for disease detection, self-management behavior, and quality of life in type 2 diabetes mellitus. J Psychosom Res. 2009 ; 67 (4). 297-305
28. Hilakivi-Clarke LA, Wozniak KM, Durcan MJ, Linnoila M. Behavior of streptozotocin-diabetic mice in tests of exploration, locomotion, anxiety, depression and aggression. Physiol Behav. 1990 ; 48 (3). 429-433
29. Holguin F, Rojas M, Hart CM. The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese mice. Lung. 2007 ; 185 (6). 367-372
30. Jacob RJ, Fan X, Evans ML, Dziura J, Sherwin RS. Brain glucose levels are elevated in chronically hyperglycemic diabetic rats: no evidence for protective adaptation by the blood brain barrier. Metabolism. 2002 ; 51 (12). 1522-1524
31. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006 ; 49 (5). 837-845
32. Koopmans B, Pouwer F, de Bie RA, van Rooij ES, Leusink GL, Pop VJ. Depressive symptoms are associated with physical inactivity in patients with type 2 diabetes. The DIAZOB Primary Care Diabetes study. Fam Pract. 2009 ; 26 (3). 171-173
33. Lauterbach D, Vora R, Rakow M. The relationship between posttraumatic stress disorder and self-reported health problems. Psychosom Med. 2005 ; 67 (6). 939-947
34. Lee SM, Bressler R. Prevention of diabetic nephropathy by diet control in the db/db mouse. Diabetes. 1981 ; 30 (2). 106-111
35. Levitt Katz LE, Swami S, Abraham M, et al. Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children. Pediatr Diabetes. 2005 ; 6 (2). 84-89
36. Lu M, Sarruf DA, Talukdar S, et al. Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med. 2011 ; 17 (5). 618-622
37. Lustman PJ, Anderson RJ, Freedland KE, de GM, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000 ; 23 (7). 934-942
38. Maeda T, Kiguchi N, Fukazawa Y, Yamamoto A, Ozaki M, Kishioka S. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice. Neuropsychopharmacology. 2007 ; 32 (5). 1133-1140
39. Malone JI, Hanna S, Saporta S, et al. Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory. Pediatr Diabetes. 2008 ; 9 (6). 531-539
40. Maren S. Is there savings for pavlovian fear conditioning after neurotoxic basolateral amygdala lesions in rats?. Neurobiol Learn Mem. 2001a ; 76 (3). 268-283
41. Maren S. Neurobiology of Pavlovian fear conditioning. Annu Rev Neurosci. 2001b ; 24: 897-931
42. Marino JS, Xu Y, Hill JW. Central insulin and leptin-mediated autonomic control of glucose homeostasis. Trends Endocrinol Metab. 2011 ; 22 (7). 275-285
43. Messier C, Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res. 1996 ; 75 (1-2). 1-11
44. Miller SA, Mancuso CA, Boutin-Foster C, et al. Associations between posttraumatic stress disorder and hemoglobin A1(C) in low-income minority patients with diabetes. Gen Hosp Psychiatry. 2011 ; 33 (2). 116-122
45. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio P. Diabetes mellitus in schizophrenic patients. Comprehensive Psychiatry. 1996 ; 37 (1). 68-73
46. Mukherjee S, Schnur DB, Reddy R. Family history of type-2 diabetes in schizophrenic patients. Lancet. 1989 ; 1 (8636). 495
47. Porsolt RD, Brossard G, Hautbois C, Roux S. Rodent models of depression: forced swimming and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci. 2001 ;:
48. Pouwer F. Should we screen for emotional distress in type 2 diabetes mellitus?. Nat Rev Endocrinol. 2009 ; 5 (12). 665-671
49. Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. ScientificWorldJournal. 2010 ; 10: 321-328
50. Reger MA, Watson GS, Frey WH, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006 ; 27 (3). 451-458
51. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006 ; 29 (2). 345-351
52. Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, Fard YY, Dehpour AR. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res. 2011 ; 224 (2). 336-343
53. Schwartz MW, Porte D. Diabetes, obesity, and the brain. Science. 2005 ; 307 (5708). 375-379
54. Schwarz E, Bahn S. Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Expert Rev Mol Diagn. 2008 ; 8 (2). 209-216
55. Senador D, Kanakamedala K, Irigoyen MC, Morris M, Elased KM. Cardiovascular and autonomic phenotype of db/db diabetic mice. Exp Physiol. 2009 ; 94 (6). 648-658
56. Sentissi O, Epelbaum J, Olie JP, Poirier MF. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull. 2008 ; 34 (6). 1189-1199
57. Sharma AN, Elased KM, Garrett TL, Lucot JB. Neurobehavioral deficits in db/db diabetic mice. Physiol Behav. 2010a ; 101 (3). 381-388
58. Sharma AN, Elased KM, Lucot JB. Alteration of monoamines processing in the brain of db/db diabetic mice. Diabetes. 2010b ; 59: A264
59. Sharma AN, Lucot JB, Garrett TL, Elased KM. Depression and psychosis-like behavior in db/db diabetic mice. Diabetes. 2010c ; 59: A671 - A672
60. Tartaglia LA, Dembski M, Weng X, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995 ; 83 (7). 1263-1271
61. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus - A randomized, controlled, double-blind trial. JAMA. 1998 ; 280 (17). 1490-1496
62. Thal SC, Heinemann M, Luh C, Pieter D, Werner C, Engelhard K. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-gamma-independent mechanisms. J Neurotrauma. 2011 ; 28 (6). 983-993
63. Trento M, Kucich C, Tibaldi P, et al. A study of central serotoninergic activity in healthy subjects and patients with type 2 diabetes treated by traditional one-to-one care or Group Care. J Endocrinol Invest. 2010 ; 33 (9). 624-628
64. Trief PM, Ouimette P, Wade M, Shanahan P, Weinstock RS. Post-traumatic stress disorder and diabetes: co-morbidity and outcomes in a male veterans sample. J Behav Med. 2006 ; 29 (5). 411-418
65. Tsuruta R, Fujita M, Ono T, et al. Hyperglycemia enhances excessive superoxide anion radical generation, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats. Brain Res. 2010 ; 1309: 155-163
66. Weiss T, Skelton K, Phifer J, et al. Posttraumatic stress disorder is a risk factor for metabolic syndrome in an impoverished urban population. Gen Hosp Psychiatry. 2011 ; 33 (2). 135-142
67. Widerlov E, Lindstrom LH, Wahlestedt C, Ekman R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res. 1988 ; 22 (1). 69-79
68. Yasuhara A, Chaki S. Metabotropic glutamate receptors: potential drug targets for psychiatric disorders. Open Med Chem J. 2010 ; 4: 20-36
69. Zhao W, Chen Y, Lin M, Sigal RJ. Association between diabetes and depression: sex and age differences. Public Health. 2006 ; 120 (8). 696-704
70. Zupancic ML, Mahajan A. Leptin as a neuroactive agent. Psychosom Med. 2011 ; 73 (5). 407-414